An observational study in Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2) and Diabetes in Children, sponsored by Medtronic MiniMed, Inc.. Completed at 5 sites in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Medtronic MiniMed, Inc. (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Diabetes Mellitus by Medtronic — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus · Medtronic.
Among the 35 studies in Diabetes Mellitus by Medtronic, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 35th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →4 of the 35 studies in Diabetes Mellitus by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic MiniMed, Inc. · Sites in Belgium, Denmark, Israel and 1 more country
Ages 2+
Medtronic Vascular · Sites in Australia, Belgium, Germany and 6 more countries
Ages 18+
Medtronic Vascular · Sites in United States, Australia, Germany and 3 more countries
Ages 18–80
Medtronic MiniMed, Inc. · Sites in France, Germany, Italy and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2026.
This study's enrollment of 59 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 83 across the 29 interventional studies, 64 across the 6 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic MiniMed, Inc., one of the names counted as Medtronic. Under that name alone:
Medtronic MiniMed, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
2 of the studies in Diabetes Mellitus by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07227805Medtronic MiniMed, Inc.Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS) | 2027-03-17 |
| NCT07115953Medtronic VascularStreamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Diabetes Mellitus by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess MiniMed Fit Payload adhesive components in different wear locations over a 7-day period to support development of the future commercialized patch pump in participants 7-17 years of age.
Investigational Centers, example, primary care clinic, academic institution, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants with insulin-requiring diabetes using the MiniMed Fit Payload adhesive components in different wear locations over a 7-day period.
Device: MiniMed Fit Payload adhesive components
The MiniMed Fit Payload device used in this study will be made of polycarbonate materials, will not contain any electronic or mechanical components, and is intended to mimic the shape and weight of a future product. Each device will consist of the payload assembly and an adhesive patch, which will be adhered to the payload on one side and the subject's skin on the other.
Summary of device survival
The number of MiniMed Fit Payload that remain securely attached to the skin at the end of day 7. This is a descriptive endpoint.
Time frame: 7 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2026 to primary completion in Aug 2026, 1 month.
Of 109 industry-sponsored observational studies under Diabetes Mellitus, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's 1 month is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.